Slowing sales growth for the company's hepatitis C drugs may have some Wall Street money managers cautious, but with the company's shares on sale, everyday investors may find that there's value in buying this beaten-up biotech.
Pfizer's acquisition of Anacor shows M&A is alive and well for biotech companies with late-stage research programs.
Sarepta Therapeutics, Synergy Pharmaceuticals, and Celator Pharmaceuticals all hope to have drugs on the market soon.
Venclexta's approval in CLL is important, but another drug making its way to market could reduce its use someday.
Understanding the level of risk in a therapeutic pipeline leads to smarter investing. Our contributors tip you off on where to be wary, and what benchmarks to look for.
With the Allergan merger now dead, Pfizer will probably look to these catalysts to improve its valuation.
New drug approvals on the horizon set the stage for a market share brawl.
With Allergan now in the rearview mirror, Pfizer may seek to the move the needle by acquiring one of these three drug developers.
Despite AstraZeneca's strategy to return to growth, income investors may still want to focus their attention on AbbVie.
Among the largest drugmakers, there are some large dividend yields, but one stands out as most likely to pay off handsomely for investors down the road.